Rethinking Substance Abuse: What the Science Shows, and What We Should Do about It

 

While knowledge on substance abuse and addictions is expanding rapidly, clinical practice still lags behind. This book brings together leading experts to describe what treatment and prevention would look like if it were based on the best science available. The volume incorporates developmental, neurobiological, genetic, behavioral, and social–environmental perspectives. Tightly edited chapters summarize current thinking on the nature and causes of alcohol and other drug problems; discuss what works at the individual, family, and societal levels; and offer robust principles for developing more effective treatments and services.

 

William R. Miller, PhD, is Emeritus Distinguished Professor of Psychology and Psychiatry at the University of New Mexico. He introduced motivational interviewing in a 1983 article and in the first edition of Motivational Interviewing (1991), coauthored with Stephen Rollnick. Dr. Miller’s research has focused particularly on the treatment and prevention of addictions and more broadly on the psychology of change. He is a recipient of two career achievement awards from the American Psychological Association, the international Jellinek Memorial Award, and an Innovators Award from the Robert Wood Johnson Foundation, among many other honors. His publications include 65 books and over 400 articles and chapters. His website is https://williamrmiller.net.

Kathleen M. Carroll, PhD, until her death in 2020, was Albert E. Kent Professor of Psychiatry, Yale School of Medicine, and Director of Psychosocial Research in the Division on Addictions. A leader in the field of addiction treatment research, she authored or coauthored over 330 articles in peer-reviewed publications, over 50 chapters in major textbooks, and several books and published manuals. Dr. Carroll was a past president of Division 50 (Addictions) of the American Psychological Association, and received both Senior Scientist and MERIT awards from the National Institute on Drug Abuse, the latter being awarded to the top 1% of National Institute of Health investigators.
,